Abstract 1849
Background
Breast cancer is one of the leading cancers for women worldwide. Mammography is the most widely used to screen breast cancer, although it is inaccurate in young women or women with dense breasts in Korea and Asian countries. Since tumor cells are often under extremely high oxidative or hypoxia, it is widely accepted that Trx1 express high level in malignant cells. Trx1 as a biomarker in blood for breast cancer detection by studies of Trx1 gene and protein expression differences in many malignant tissues and bloods from various cancer patients. It has been shown that gene expression level of Trx1 was the highest in breast cancer tissue among many different cancers in contrast to the lowest in normal breast tissue. Therefore, it would be interesting to examine whether the quantitation of Trx1 from blood could be a tool to detect breast cancer and to complement mammography.
Methods
We have developed an ELISA kit quantitating Trx1. Trx1 levels of bloods from 116 normal healthy women, 140 confirmed breast cancer patients with stage from 0 to 4, and each 30 confirmed patients of lung, ovarian, gastric, colorectal, and cervical cancer have been estimated by the kit. The test results were analyzed by ROC curve, one-way ANOVA test, and unpaired t-test.
Results
The mean value of Trx1 level from normal women was 7.506 (U/mL) and that from breast cancer patients was 37.75. The Trx1 level clearly differentiated breast cancers from normal cases with sensitivity of 96.4% and specificity of 99.1% (AUC 0.990, p < 0.001). Each level of Trx1 from lung (16.7), ovarian (15.50), gastric (15.66), colorectal (16.39), and cervical (22.51) cancer was below the cut-off value (22.8 U/mL) for breast cancer detection. We compared normal women to breast cancer patients’ Trx1 levels and BI-RADS categories. Among the normal women, the false positive rate of mammography was 26% whereas that of Trx1 quantitation was 1%. Among the breast cancer patients, the false negative rate of mammography was 24.82% and that of Trx1 quantitation was 3.76%.
Conclusions
These results indicated that the blood level of Trx1 quantitation estimated by the ELISA kit could be an effective and specific modality to detect breast cancer from blood and also could complement current limits of mammography for small and dense breasts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3902 - The efficacy of preoperative breast cancer chemotherapy without anti-HER2-targeted treatment – single center experience in setting of no reimbursement in Poland (2011-2015)
Presenter: Agnieszka Badora-Rybicka
Session: Poster Display session 2
Resources:
Abstract
4733 - A Multicentre, International Neoadjuvant (NA), Randomized, Double-blind Phase III Trial comparing FULVESTRANT to a combination of FULVESTRANT and PALBOCICLIB in patients with operable Luminal Breast Cancer (SAFIA Trial)
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 2
Resources:
Abstract
5227 - Outcome of Non-metastatic Male Breast Cancer: 222 patients
Presenter: Ulku Yalcintas Arslan
Session: Poster Display session 2
Resources:
Abstract
5943 - Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, Her2 positive breast cancer in a limited resources setting: ML25232 study final results
Presenter: Samir Beslija
Session: Poster Display session 2
Resources:
Abstract
1725 - Final results of scalp cooling for hair preservation: A single- institution prospective study.
Presenter: Dario Loparco
Session: Poster Display session 2
Resources:
Abstract
3713 - Adjuvant Systemic Therapy in Women with Early Breast Cancer and Intermediate Prosigna ROR Scores: Is Chemotherapy Use Declining? Evidence From a Large Practice
Presenter: Lowell Hart
Session: Poster Display session 2
Resources:
Abstract
818 - Management of early breast cancer in women over 90: A 10 year experience
Presenter: Emily Coffey
Session: Poster Display session 2
Resources:
Abstract
1141 - Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early- stage breast cancer.
Presenter: Daniel Reinhorn
Session: Poster Display session 2
Resources:
Abstract
2277 - Hepatitis B screening and incidence of flare among non-metastatic breast cancer patients treated with anthracyclines
Presenter: Zewen Zhang
Session: Poster Display session 2
Resources:
Abstract
2781 - Effect of denosumab on low bone mineral density in postmenopausal Japanese early breast cancer patients receiving aromatase nhibitors : 36-month results
Presenter: Koichi Sakaguchi
Session: Poster Display session 2
Resources:
Abstract